Skip to main content

Novo Nordisk A/S (NVO)

NYSE: NVO · Delayed Price · USD
102.10 1.23 (1.22%)
Sep 23, 2021 4:00 PM EDT - Market closed
Market Cap179.61B
Revenue (ttm)20.79B
Net Income (ttm)7.10B
Shares Out2.29B
EPS (ttm)3.02
PE Ratio33.85
Forward PE29.76
Dividend$1.47 (1.44%)
Ex-Dividend DateAug 16, 2021
Volume524,031
Open102.22
Previous Close100.87
Day's Range101.87 - 102.53
52-Week Range61.99 - 107.24
Beta0.27
AnalystsHold
Price Target72.31 (-29.2%)
Est. Earnings DateNov 3, 2021

About NVO

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration a...

IndustryPharmaceuticals
Founded1923
CEOLars Fruergaard Joergensen
Employees45,971
Stock ExchangeNYSE
Ticker SymbolNVO
Full Company Profile

Financial Performance

In 2020, NVO's revenue was 126.95 billion, an increase of 4.04% compared to the previous year's 122.02 billion. Earnings were 42.14 billion, an increase of 8.18%.

Financial numbers in millions DKKFinancial Statements

Analyst Forecast

According to 3 analysts, the average rating for NVO stock is "Hold." The 12-month stock price forecast is 72.31, which is a decrease of -29.18% from the latest price.

Price Target
$72.31
(-29.18% downside)
Analyst Consensus: Hold

News

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S – Share repurchase programme

1 week ago - GlobeNewsWire

The 10 Richest People on Wall Street and How to Invest in Them

Knowing what stocks the richest people on Wall Street currently own could help you find potential winners for your portfolio. The post The 10 Richest People on Wall Street and How to Invest in Them appe...

Other symbols:AAPLBACBXIEPKOKRRH
1 week ago - InvestorPlace

Here's Why Novo Nordisk (NVO) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

2 weeks ago - Zacks Investment Research

2 Top Healthcare Stocks That Could Boost Your Portfolio in September (and Beyond)

These two companies have outperformed the market in the past year, and they are likely to continue doing so.

Other symbols:HCA
2 weeks ago - The Motley Fool

Analysts Differ Most About Potential for Novo's Weight-Loss Drug

Novo Nordisk AS's ( NVO , Financial) weight-loss drug is biopharma's most controversial blockbuster, according to a report from Evaluate Pharma. The highest and lowest forecasts for the Danish company's...

Other symbols:BIIBITCIMRKPFEVIR
2 weeks ago - GuruFocus

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S – Share repurchase programme

2 weeks ago - GlobeNewsWire

3 Big Drug/Biotech Outperformers Worth Keeping an Eye On (Revised)

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

Other symbols:BIIBBNTXGSKJNJLLYPFE
4 weeks ago - Zacks Investment Research

House Committee Questions Eli Lilly, Sanofi, Novo Nordisk On 'Unacceptably High' Insulin Prices

House Energy & Commerce Committee leaders sent three letters to execs at Eli Lilly And Co (NYSE: LLY), Sanofi SA (NASDAQ: SNY), and Novo Nordisk A/S (NYSE: NVO), raising concerns that despite their supp...

Other symbols:LLYSNY
1 month ago - Benzinga

3 Big Drug/Biotech Outperformers Worth Keeping an Eye On

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

Other symbols:BIIBBNTXGSKJNJLLYPFE
1 month ago - Zacks Investment Research

3 Low-Risk Stocks for Conservative Investors

Protecting capital can be just as important as growing it.

Other symbols:ACNV
1 month ago - The Motley Fool

Novo Nordisk CEO on product pricing: Our numbers are 'declining year-on-year'

Novo Nordisk CEO Lars Fruergaard Jørgensen joins Yahoo Finance's Julie Hyman to break down the company's strong second-quarter earnings, assess the pharmaceutical space amid the pandemic, and discuss th...

1 month ago - Yahoo Finance

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 10 August 2021

Bagsværd, Denmark, 11 August 202 1 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated person...

1 month ago - GlobeNewsWire

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 9 August 2021

Bagsværd, Denmark, 10 August 202 1 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated person...

1 month ago - GlobeNewsWire

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 5 August 2021

Bagsværd, Denmark, 9 August 202 1 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons...

1 month ago - GlobeNewsWire

Here Are the Winners of Cowen's Big Pharma R&D Showdown

The Wall Street firm put big drugmakers' R&D programs through five different tests.

Other symbols:ABBVLLYMRKNVSPFE
1 month ago - The Motley Fool

Novo Nordisk's (NVO) Q2 Earnings and Sales Beat Estimates

Novo Nordisk (NVO) delivers better-than-expected results for Q2. Sales are aided by growth in Diabetes and Obesity Care owing to elevated GLP-1 revenues.

1 month ago - Zacks Investment Research

BofA Upgrades Novo Nordisk, Says Wegovy Obesity Drug Launch 'Far Exceeded' Expectations

Novo Nordisk A/S (NYSE:NVO) shares traded higher by 3.2% on Thursday morning after the insulin and diabetes care leader landed a major Wall Street upgrade. The Analyst: Bank of America analyst Sachin Ja...

1 month ago - Benzinga

Novo Nordisk Raises Forecasts on New Obesity Drug

Aug.05 -- Lars Fruergaard Jorgensen, Novo Nordisk chief executive officer, discusses first half earnings results. The Danish drug-maker raised its profit and sales forecasts for the year, reflecting hig...

1 month ago - Bloomberg Markets and Finance

Novo Nordisk Shares Are Trading Higher As GLP-1 Treatments Boost Q2 Topline, Bottom-line

Novo Nordisk A/S (NYSE: NVO) Q2 sales increased 10% Y/Y (17% at CER) to DKK 33.04 billion. Sales in International Operations increased 13% (17% CER) at DKK18.2 billion, and sales in North America Operat...

1 month ago - Benzinga

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S – Share repurchase programme

1 month ago - GlobeNewsWire

Why Is Novo Nordisk Buying a Rare-Disease Candidate?

The company is mainly known for its diabetes drugs but has some background in rare-disease drugs.

Other symbols:PRTA
1 month ago - The Motley Fool

11 Safe Stocks for Superior Gains

Finding safe stocks with the potential to deliver outsized gains can be challenging, but this list of names is certainly a good place to start.

2 months ago - Kiplinger

Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk

Prothena (PRTA) announces an agreement to sell its clinical-stage antibody, PRX004, and the broader ATTR amyloidosis program for $1.2 billion to Novo Nordisk.

Other symbols:PRTA
2 months ago - Zacks Investment Research

Novo Nordisk To Buy Prothena's ATTR Amyloidosis Program For Up To $1.2B

Novo Nordisk A/S (NYSE: NVO) will acquire Prothena Corporation plc's  (NASDAQ: PRTA) and clinical stage antibody PRX004 and broader ATTR amyloidosis program. PRX004 is a Phase 2 ready immunotherapy desi...

Other symbols:PRTA
2 months ago - Benzinga

Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 billion

Danish drugmaker Novo Nordisk will acquire U.S. drug developer Prothena Corp's experimental heart therapy, PRX004, in a deal that could be worth up to $1.23 billion, the companies said on Monday.

Other symbols:PRTA
2 months ago - Reuters